FDA finds peeling paint, debris at U.S. plant making J&J’s COVID-19 vaccine

The U.S. Food and Drug Administration (FDA) said it had found problems including peeling paint and loose debris during inspections at a U.S. plant in Baltimore that makes Johnson & Johnson’s COVID-19 vaccine and asked for remediation of the issues. Emergent Biosolutions, which owns the plant, has been seeking regulatory authorization to make the J&J vaccine there. It stopped production at the plant recently, saying the FDA had asked it to do so after an inspection.